title: Placenta growth factor (PlGF) mRNA expression in brain tumors.
abstract: To investigate the relationship between placenta growth factor (PlGF) and brain tumor angiogenesis, we screened 36 primary and 3 metastatic brain tumors. We examined the expression of PlGF mRNA with respect to vasculature of various tumors which was determined by preoperative angiography. The expression of genes of the other angiogenic factors, vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) was also tested, and compared to that of PlGF. The primary tumors consisted of 16 meningiomas, 7 gliomas, 7 schwannomas, 4 pituitary adenomas, 1 germinoma, and 1 choriocarcinoma. Using a quantitative reverse transcription-polymerase chain reaction, the mRNA for PlGF149 and PlGF170 were detected in 25 out of 39 (64.1%) brain tumors. In primary brain tumors, PIGF mRNA was expressed in all the hypervascular tumors, but only in 5 of 16 hypovascular tumors (31.3%). None of the 3 metastatic hypervascular tumors expressed PlGF mRNA. The VEGF and bFGF mRNA expression was both detected in 87.2% of the tumors examined. We conducted hypoxic experiments with cultured U-251MG human glioma cells to determine the mechanism of PIGF gene regulation. As the atmospheric oxygen concentration was decreased, the PIGF mRNA level in the U-251MG cells was markedly increased. These results suggest that PIGF may contribute to the pathogenesis of brain tumor angiogenesis.
authors.affiliation: Department of Neurosurgery, Kanazawa University School of Medicine, Japan. nomunomu@med.kanazawa-u.ac.jp
authors.forename: M
authors.initials: M
authors.lastname: Nomura
authors.forename: S
authors.initials: S
authors.lastname: Yamagishi
authors.forename: S
authors.initials: S
authors.lastname: Harada
authors.forename: T
authors.initials: T
authors.lastname: Yamashima
authors.forename: J
authors.initials: J
authors.lastname: Yamashita
authors.forename: H
authors.initials: H
authors.lastname: Yamamoto
mesh_terms: D043925:Angiogenesis Inducing Agents / Q000096:biosynthesis*; D001932:Brain Neoplasms / Q000378:metabolism* / Q000473:pathology; D002460:Cell Line; D017931:DNA Primers; D004273:DNA, Neoplasm / Q000096:biosynthesis; D016228:Endothelial Growth Factors / Q000494:pharmacology; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D005910:Glioma / Q000378:metabolism / Q000473:pathology; D006801:Humans; D000860:Hypoxia / Q000378:metabolism; D008222:Lymphokines / Q000494:pharmacology; D009389:Neovascularization, Pathologic / Q000473:pathology; D000072483:Placenta Growth Factor; D011061:Poly A / Q000096:biosynthesis; D011257:Pregnancy Proteins / Q000096:biosynthesis*; D012333:RNA, Messenger / Q000096:biosynthesis*; D012334:RNA, Neoplasm / Q000096:biosynthesis*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D043925:Angiogenesis Inducing Agents; D017931:DNA Primers; D004273:DNA, Neoplasm; D016228:Endothelial Growth Factors; D008222:Lymphokines; C000608036:PGF protein, human; D011257:Pregnancy Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D016222:Fibroblast Growth Factor 2; D000072483:Placenta Growth Factor; D011061:Poly A